ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Henles to Get Bristol-Myers $25,000 Award

March 23, 1979

President’s Cancer Panel Seeks Ways to Open Grants For More New Ideas

December 19, 1980

Scripps, Sandoz Deal Becomes Case Study As NI Rethinks Sponsored Research

January 28, 1994

Evidence Lacking On Value of Vitamins to Prevent Disease, Panel Says.

June 16, 2006

NCAB Votes to Bring Organ Systems Coordinating Center Into NCI, Disperse Entire Grants Portfolio

February 12, 1988

NIH Authorization Bills Require NCI To Spend 10% On Cancer control

February 12, 1993